"Onyx has an established track record of success and a strong pipeline that could offer tremendous advances for patients and oncologists," said Dr. Love. "In addition to late-stage opportunities with Nexavar and carfilzomib, Onyx has acquired rights to a number of exciting earlier stage compounds that target some of the most innovative pathways in drug development. I look forward to partnering with Michael and the rest of the team to advance these novel molecules."
Most recently, Dr. Love was President, Chief Executive Officer, and Chairman of the Board of Directors of the biotechnology company Nuvelo, Inc. He grew Nuvelo into a late-stage development company focused on acute cardiovascular disease, cancer, and other debilitating medical conditions. Before joining Nuvelo in 2001, he served as Senior Vice President of Development at Theravance, Inc. Previously, Dr. Love spent six years at Genentech, Inc. in a number of senior management positions in Medical Affairs and Product Development. As Vice President of Product Development and Regulatory Affairs at Genentech, Dr. Love oversaw all drugs in development including Herceptin, Rituxan, and TNKase. He also served as chairman of Genentech's Product Development Committee.
Dr. Love earned his bachelor's degree in molecular biology from Haverford College and his medical degree at Yale Medical School. He completed his residency and fellowship training in internal medicine and cardiology at Massachusetts General Hospital and Harvard Medical School. Following residency training, Dr. Love joined the faculty of Massachusetts General in the department of cardiology. He currently serves on the board of directors of Affymax, Inc., Santarus, Inc., ARCA biopharma, Inc., and on the California Institute for Regenerative Me
|SOURCE Onyx Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved